A new drug called Entrectinib for the treatment of children and adults with cancer that has recurred or is resistant to treatment, including brain cancers
About Entrectinib –
Entectinib is a drug that is taken orally and works against genetic changes in NTRK1/ 2/3, ROS1, ALK. The drug also has the ability to penetrate the “blood-brain barrier” and thus reach tumors in the brain and spinal cord.
The study, called STARTRK-NG, is still open for recruitment in the United States and includes patients aged 0-21 years who have failed several lines of treatment.
Initial results presented – STRIKING …
The preliminary results were presented at the annual international oncology conference, the ASCO, and were defined by the scientific committee as “striking”:
The first 16 patients received treatment and 11 responded. Those who did not respond – lived more than 50 days and those who responded to treatment – lived more than 200 days. It should be noted that this is a particularly difficult population of patients. The patients in the study so far had brain tumors, various types of sarcoma, neuroblastoma and other.
During the presentation of the initial results, a number of brain images of children and young adults with aggressive brain tumors were presented and were unusually impressive by the results of the treatment with Entrectinib!
The study is expected to recruit 65 patients and is open only in the United States.
Be strong and determined forever ❣
TRIAL•IN Pharma offers a unique, personalized search for patients with metastatic cancer and malignant brain tumors, which reveals advanced and innovative cancer treatments worldwide and helps to achieve them.
For free service assessment to our service, dial 24/7
+44.2082.426.039 or contact us through our website
Do not give up on life!